ClinicalTrials.gg
RecruitingNCT06890312HERA-PCIUpdated May 26, 2026

Timing of Anticoagulant Administration During Radial Access Percutaneous Coronary Intervention: the HERA-PCI Study (Heparin Early for Radial Access Percutaneous Coronary Intervention)

An interventional study of Administration of heparin after sheath insertion and Administration of heparin prior to sheath insertion in Coronary Angiography, Percutaneous Coronary Intervention and Radial Artery Occlusion, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-26.

Sponsored by University Hospital, Strasbourg, France · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
550
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Arterial Occlusive Diseases with a site in France — 4 open to participants now, 5 under way, none of them phase 3. Arterial Occlusive Diseases · France.

Started
2025
the only one that year
No phase
8 of 15
3 open now
Registered
14th of 15
by date

Among the 15 studies in Arterial Occlusive Diseases with a site in France, this one is the only one that started in 2025, is one of 8 with no phase, and was the 14th registered.

Arterial Occlusive Diseases

230 studies on the registry are indexed under Arterial Occlusive Diseases; 27 are open to participants now.

Browse Arterial Occlusive Diseases studies →

Open to participants now

4 of the 15 studies in Arterial Occlusive Diseases with a site in France are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 20 Arterial Occlusive Diseases studies recruiting now, 13 (65%) set no upper age limit and 2 (10%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Arterial Occlusive Diseases with a site in France, or all of them as a file.
02

Study summary

While the reduced hemorrhagic risk of radial access for percutaneous coronary intervention compared to femoral access is well-established, its main complication remains radial artery occlusion, which can occur in up to 30% of patients. Anticoagulation is the primary preventive measure recommended in clinical practice to reduce the risk of this complication, typically involving heparin injection during the procedure in most centers. However, data on the effect of the timing of heparin injection are limited. The investigators hypothesize that injection of heparin before sheath insertion may reduce the rate of radial artery occlusion compared with injection after sheath insertion.

Read the detailed description

Prevention of radial occlusion relies on optimal hemostasis and anticoagulation. Previous studies have demonstrated a decrease incidence of radial artery occlusion through hemostasis at the puncture site using short-duration mechanical compression methods, guided by mean arterial pressure measurement, or clinical tests evaluating hand vascularization. Anticoagulation plays a central role in the prevention of radial occlusion. It is currently recommended to administer a systemic anticoagulant during a procedure using radial access. Despite the lack of consensus on the nature of the anticoagulant, an international survey showed that more than 90% of interventional cardiologists use unfractionated heparin. The intensity of anticoagulation is also associated with the risk of radial artery occlusion, with previous studies showing that the risk is reduced with the use of "high doses" (5000 IU or 75 IU/kg) compared to "low doses" (\<5000 IU or \<50 IU/kg). A randomized controlled trial did not show any difference between intravenous and intra-arterial heparin injection via the sheath. No studies have examined the timing of anticoagulant administration relative to sheath insertion. In current practice, anticoagulant administration is typically done after sheath insertion in the radial artery. This common practice likely stems from historical concerns about conversion to femoral access (which is now rare due to improved devices for radial puncture and less consequential due to vascular closure systems used in femoral access, significantly reducing hemorrhagic risk).

No data is currently available on the optimal timing of anticoagulant administration, despite the potential modification of its local effect if the sheath is already in place in the radial artery during the anticoagulant injection, obstructing the radial artery lumen. Our hypothesis is that intravenous anticoagulant administration before sheath insertion in the radial artery is more effective than administration after sheath insertion in patients undergoing percutaneous coronary intervention via radial access. The expected outcomes include a reduction in the incidence of radial artery occlusion after the procedure, leading to a decrease in potential complications (acute hand ischemia, failure of the access route during a subsequent procedure, inability to create an ipsilateral arteriovenous fistula).

The primary objective is to evaluate the impact of the timing (early or late) of intravenous anticoagulant administration on the risk of radial occlusion during a percutaneous coronary intervention via radial access.

This is a single-center, comparative, randomized, single-blind study with blinded evaluation of the primary endpoint.

After providing information and verifying eligibility criteria, the investigator will obtain the patient's free, informed, and written consent before any intervention, on the day the coronary angiography is scheduled. Consent will be obtained in the patient's hospital room (Cardiology Day Hospital or conventional hospitalization unit).

Randomization, in blocks of variable sizes, will be carried out by the investigator (or a delegate) after consent is signed and eligibility criteria are verified and before the percutaneous coronary intervention via radial access. Randomization assigns the subject's inclusion number and treatment group:

  • Control group "delayed injection": administration of heparin after sheath insertion
  • Experimental group "early injection": administration of heparin before sheath insertion Randomization will be done via a centralized electronic system called Cleanweb.

The percutaneous coronary intervention via radial access will be performed according to standard practice in the cardiac catheterization lab of our center. At the time of installation, the operator will palpate the radial pulse to ensure the feasibility of radial access. In the experimental group "early injection" of heparin, the injection will be done intravenously just before skin disinfection, approximately 5 minutes (± 3 minutes) before the puncture. In the control group "delayed injection", the injection will be done 5 minutes (± 3 minutes) after sheath insertion into the radial artery (protocol used in daily practice). If radial puncture fails, patients will be excluded from the primary endpoint analysis but will be followed up at 30 days for secondary endpoints. The heparin bolus dose will systematically be 50 IU/kg. At the end of the procedure, an ACT will be measured just before sheath removal, and hemostasis at the puncture site will be achieved using a TR-band® mechanical compression device. This will be placed before sheath removal and inflated with a syringe containing 15 cc of air for all patients. According to local protocol, mechanical compression is left in place for 2 hours before gradual deflation (removal of 2 cc every 15 minutes until complete deflation, bracelet left in place for 30 minutes post-deflation, then removed and replaced with a simple dressing). In case of additional coronary angioplasty, the heparin dose will be adjusted based on the angioplasty indication at the operators' discretion for a total dose of 0.7 to 1.0 mg/kg, aiming for an ACT > 250 ms.

At day 1, the following will be performed according to standard practice:

  • An interview
  • A clinical examination
  • An upper limb arterial Doppler ultrasound on the same side as the radial puncture

At day 30 (±7 days), patients will be contacted by phone specifically for the research by the investigators and co-investigators involved in the study. The telephone interview will consist of an inquiry for symptoms of radial occlusion or major cardiovascular events. If symptoms of radial occlusion are detected, the patient will be scheduled for a consultation with a clinical examination, pulse palpation, Barbeau maneuver, and upper limb arterial Doppler ultrasound on the same side as the radial puncture.

The primary endpoint is the rate of radial artery occlusion, as determined by Doppler ultrasound at day 1.

The secondary endpoints are:

  • The rate of symptomatic radial artery occlusion (acute hand ischemia) on day 1. The rate of occlusion will be assessed through a thorough clinical examination on day 1 after the procedure, and if necessary, based on clinical findings, by an upper limb CT angiography. A telephone interview will also be conducted on day 30 to check for symptoms of symptomatic radial artery occlusion (signs of hand ischemia). If symptoms are present, the patient will be scheduled for a consultation with arterial Doppler ultrasound to confirm or rule out radial occlusion.
  • Major cardiovascular events within the first 30 days following the percutaneous coronary intervention: cardiovascular death, myocardial infarction, and stroke. These events will be assessed during the visits on day 1 and day 30.
  • Local hemorrhagic events assessed by checking for a hematoma of at least 2 cm on day 1 and general hemorrhagic events evaluated on day 30 according to the BARC (Bleeding Academic Research Consortium) classification.
  • Local functional impact evaluated on day 30 by the presence of residual pain in the radial region or limited joint mobility.
  • The rate of radial puncture failure.
  • The occurrence of all-cause mortality on day 30.
03

Conditions studied

  • Coronary Angiography
  • Percutaneous Coronary Intervention
  • Radial Artery Occlusion
  • Bleeding
  • Anticoagulation

Keywords

  • Anticoagulant injection timing
  • Percutaneous coronary intervention
  • Coronary angiography
  • Radial artery occlusion prevention
  • Bleeding events
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients having 18 years old or older, regardless of gender, undergoing percutaneous radial coronary intervention
  • Subject affiliated to a social protection health insurance
  • Subject able to understand the objectives and risks of the research and to provide dated and signed consent
  • Subject who has been informed of the results of the preliminary medical examination

Exclusion criteria

Exclusion Criteria:

  • to the use of heparin (history of heparin-induced thrombocytopenia)
  • Very high bleeding risk defined by recent bleeding (\<6 months) of type 3 of the BARC classification
  • Subject in an exclusion period (determined by a previous or ongoing study)
  • Inability to give the subject enlightened information (subject in an emergency situation, difficulties in understanding the subject, etc.)
  • Subject under safeguard of justice
  • Subject under guardianship or curatorship
  • Pregnancy
  • Breastfeeding
  • Patient on anticoagulant treatment: anti-vitamin K, direct oral anticoagulants (DOACs).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
550 participants (estimated)

Study arms

  • Active comparator
    "heparin delayed injection"

    Administration of heparin after sheath insertion

    Procedure: Administration of heparin after sheath insertion

  • Experimental
    heparin early injection

    Administration of heparin prior to sheath insertion

    Procedure: Administration of heparin prior to sheath insertion

Interventions

  • ProcedureAdministration of heparin after sheath insertion

    Administration of heparin after sheath insertion

  • ProcedureAdministration of heparin prior to sheath insertion

    Administration of heparin prior to sheath insertion

06

What researchers measure

Primary outcomes

  1. Rate of radial artery occlusion

    The primary endpoint is the rate of radial artery occlusion, as determined by Doppler ultrasound at day 1.

    Time frame: Day 1

Secondary outcomes

  1. Rate of symptomatic radial artery occlusion (acute hand ischemia) on day 1

    The rate of symptomatic radial artery occlusion (acute hand ischemia) on day 1. The rate of occlusion will be assessed through a thorough clinical examination on day 1 after the procedure, and if necessary, based on clinical findings, by an upper limb CT angiography. A telephone interview will also be conducted on day 30 to check for symptoms of symptomatic radial artery occlusion (signs of hand ischemia). If symptoms are present, the patient will be scheduled for a consultation with arterial Doppler ultrasound to confirm or rule out radial occlusion.

    Time frame: Day1

  2. Major cardiovascular events within the first 30 days following the percutaneous coronary intervention: cardiovascular death, myocardial infarction, and stroke.

    Major cardiovascular events within the first 30 days following the percutaneous coronary intervention: cardiovascular death, myocardial infarction, and stroke. These events will be assessed during the visits on day 1 and day 30

    Time frame: Day 30

  3. Local and general hemorrhagic events

    Local functional impact evaluated on day 30 by the presence of residual pain in the radial region or limited joint mobility.

    Time frame: Day 30

  4. Rate of radial puncture failure.

    The rate of radial puncture failure.

    Time frame: Day 0

  5. Rate of all-cause mortality on day 30.

    The occurrence of all-cause mortality on day 30.

    Time frame: Day 30

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jan 2028, 31 months after the start.

Of 47 non-industry interventional studies with no phase under Arterial Occlusive Diseases, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 59. This study's planned 31 months is above that.

Counting every sponsor, half of 56 studies reached it within 27 months; a quarter within 14 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2024
First posted
Mar 24, 2025
StartActual
Jun 5, 2025
Primary completionEst.
Jan 2028
CompletionEst.
Jan 2028
Last update
May 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06890312
Responsible party
Sponsor
First posted
Mar 24, 2025
Start date
Jun 5, 2025
Primary completion
Jan 2028 (estimated)
Completion
Jan 2028 (estimated)
Last update
May 26, 2026

Study contacts

Pr Patrick OHLMANN Pr Patrick OHLMANN, Professor
Contact
patrick.ohlmann@chru-strasbourg.fr
03.69.55.09.53 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion